Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Genzyme Will Pursue Cystic Fibrosis Drugs
by Michael McCoy
November 21, 2011
| A version of this story appeared in
Volume 89, Issue 47
Sanofi’sGenzyme unit has signed a research agreement with Cystic Fibrosis Foundation Therapeutics to discover drugs to treat people with Delta F508, the most common mutation found in patients with cystic fibrosis. The Delta F508 mutation prevents a protein called CFTR from moving to its proper place at the cell surface, which can impede the flow of fluids in the lungs. Researchers will search libraries at both Genzyme and Sanofi for compounds that help the CFTR protein function correctly.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X